Compare CHE & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHE | PCVX |
|---|---|---|
| Founded | 1970 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 6.1B |
| IPO Year | N/A | 2020 |
| Metric | CHE | PCVX |
|---|---|---|
| Price | $452.58 | $46.75 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $574.25 | $105.00 |
| AVG Volume (30 Days) | 139.1K | ★ 1.1M |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 18.95 | N/A |
| Revenue | ★ $2,530,634,000.00 | N/A |
| Revenue This Year | $5.91 | N/A |
| Revenue Next Year | $6.21 | N/A |
| P/E Ratio | $23.85 | ★ N/A |
| Revenue Growth | ★ 6.45 | N/A |
| 52 Week Low | $408.42 | $27.66 |
| 52 Week High | $623.61 | $93.77 |
| Indicator | CHE | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 59.42 | 52.91 |
| Support Level | $438.87 | $44.57 |
| Resistance Level | $459.55 | $49.55 |
| Average True Range (ATR) | 10.16 | 2.13 |
| MACD | 2.08 | 0.15 |
| Stochastic Oscillator | 77.47 | 52.90 |
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. Through its subsidiaries, the company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.